Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 199 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Chloroquine Clear all
Completed Phase 2 Interventional Results available

LY3214996 +/- HCQ in Pancreatic Cancer

NCT04386057
View directory record Official record
Conditions
Pancreatic Cancer, Advanced Cancer
Interventions
Hydroxychloroquine Sulfate, LY3214996
Drug
Lead sponsor
Kimberly Perez, MD
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Oct 18, 2026, 2:08 AM EDT
Suspended Phase 4 Interventional

Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care

NCT04334967
View directory record Official record
Conditions
COVID-19, Corona Virus Infection, SARS-CoV-2, 2019-nCoV, 2019 Novel Coronavirus
Interventions
Hydroxychloroquine, Vitamin C
Drug · Dietary Supplement
Lead sponsor
Providence Health & Services
Other
Eligibility
45 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 18, 2026, 2:08 AM EDT
Completed Phase 2 Interventional Results available

Chloroquine for Reducing Immune Activation in HIV- Infected Individuals

NCT00819390
View directory record Official record
Conditions
HIV Infections
Interventions
Chloroquine, Placebo
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
15
States / cities
Birmingham, Alabama • San Diego, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2014 · Synced Oct 18, 2026, 2:08 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Plaquenil for Alopecia Areata, Alopecia Totalis

NCT00176982
View directory record Official record
Conditions
Alopecia Areata
Interventions
Hydroxychloroquine
Drug
Lead sponsor
Hordinsky, Maria K., MD
Individual
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
2
States / cities
Minneapolis, Minnesota • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2009 · Synced Oct 18, 2026, 2:08 AM EDT
Completed Phase 3 Interventional Results available

An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies

NCT00720798
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab, Disease-modifying anti-rheumatic drugs, Non-steroidal anti-inflammatory drugs, Oral corticosteroids
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
2,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
138
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 119 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Oct 18, 2026, 2:08 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)

NCT04329923
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine Sulfate 400 mg twice a day, Hydroxychloroquine Sulfate 600 mg twice a day, Hydroxychloroquine Sulfate 600 mg once a day, Placebo oral tablet
Drug
Lead sponsor
Ravi Amaravadi, MD
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 18, 2026, 2:08 AM EDT
Withdrawn Phase 2 Interventional

Assessing Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19)

NCT04363866
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
Hydroxychloroquine, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Oct 18, 2026, 2:08 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19

NCT04435808
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Oct 18, 2026, 2:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

CiPA Phase 1 ECG Biomarker Validation Study

NCT03070470
View directory record Official record
Conditions
Drug-induced QT Prolongation, Pharmacokinetics, Pharmacodynamics
Interventions
Ranolazine, Verapamil, Lopinavir / Ritonavir, Chloroquine, Placebo, Dofetilide and Diltiazem
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 18, 2026, 2:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dose Escalation PfSPZ-CVac

NCT03083847
View directory record Official record
Conditions
Malaria
Interventions
Chloroquine Phosphate, Pyrimethamine, Sanaria PfSPZ Challenge
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Oct 18, 2026, 2:08 AM EDT
Terminated Phase 3 Interventional

A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients

NCT04345692
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine
Drug
Lead sponsor
Queen's Medical Center
Other
Eligibility
18 Years to 95 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 18, 2026, 2:08 AM EDT
Not yet recruiting Phase 4 Interventional

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

NCT07352566
View directory record Official record
Conditions
Psoriasis, Atopic Dermatitis
Interventions
In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil, Calcipotriene, Tapinarof, Crisaborole, Tacrolimus, Adalimumab, Etanercept, Certolizumab, Infliximab, Secukinumab, Ixekizumab, Apremilast, Risankizumab, Ustekinumab, Hydroxychloroquine, Methotrexate, Mycophenolate, Azathioprine, Chloroquine, Cyclosporine, Tofacitinib, Deucravacitinib, Dupilumab, Tralokinumab, Guselkumab, Tildrakizumab, Baractinib, Abrocitinib, Upadacitinib, Lebrikizumab, Nemolizumab, Ruxolitinib, Bimekizumab, Roflumilast
Device · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 18, 2026, 2:08 AM EDT
Withdrawn Phase 2 Interventional

A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19

NCT04379492
View directory record Official record
Conditions
COVID-19, COVID19, Sars-CoV2, SARS-Cov-2
Interventions
Hydroxychloroquine, Placebo
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 18, 2026, 2:08 AM EDT
Completed Early Phase 1 Interventional

Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine

NCT01396200
View directory record Official record
Conditions
Myeloma
Interventions
Hydroxychloroquine, Rapamycin
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 26, 2013 · Synced Oct 18, 2026, 2:08 AM EDT
Terminated Phase 2 Interventional Results available

Hydroxychloroquine Versus Pioglitazone in Combination Treatment for Type 2 Diabetes Mellitus

NCT02303405
View directory record Official record
Conditions
Diabetes Mellitus Type 2 With Hyperglycemia
Interventions
Hydroxychloroquine, Pioglitazone
Drug
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 18, 2026, 2:08 AM EDT
Terminated Phase 3 Interventional Results available

Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection

NCT04341727
View directory record Official record
Conditions
Coronavirus Infection
Interventions
Hydroxychloroquine Sulfate, Azithromycin, Chloroquine Sulfate
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 18, 2026, 2:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Trial to Determine Safety and Protective Efficacy of Sanaria PfSPZ Challenge With Concurrent Pyrimethamine Treatment That Inhibits Development of Asexual B...

NCT02511054
View directory record Official record
Conditions
Malaria
Interventions
Chloroquine (CQ), Pyrimethamine (PYR), Sanaria PfSPZ Challenge (NF54)
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 18, 2026, 2:08 AM EDT
Terminated Phase 3 Interventional

Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease

NCT04344444
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine, Azithromycin
Drug
Lead sponsor
LCMC Health
Other
Eligibility
18 Years to 100 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 18, 2026, 2:08 AM EDT
Recruiting Phase 1Phase 2 Interventional

Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma

NCT04911816
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas
Interventions
Hydroxychloroquine sulfate
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 18, 2026, 2:08 AM EDT
Terminated Phase 3 Interventional

Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)

NCT04421664
View directory record Official record
Conditions
Corona Virus Infection, SARS-CoV Infection, Coronavirus
Interventions
Hydroxychloroquine, Placebo oral tablet
Drug
Lead sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 18, 2026, 2:08 AM EDT
Completed Not applicable Interventional Results available

Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy

NCT00405275
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept, methotrexate, Sulfasalazine, Hydroxychloroquine, Placebo, triple, Placebo, etanercept
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
28
States / cities
Loma Linda, California • Long Beach, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Oct 18, 2026, 2:08 AM EDT
Terminated Phase 1Phase 2 Interventional

Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO)

NCT04120883
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Hydroxychloroquine lower dose, Hydroxychloroquine higher dose
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 18, 2026, 2:08 AM EDT
Terminated Phase 2 Interventional Results available

Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer

NCT00786682
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, hydroxychloroquine
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
7
States / cities
Hamilton, New Jersey • Montclair, New Jersey • Morristown, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 18, 2026, 2:08 AM EDT
Completed Phase 1 Interventional

Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer

NCT04132505
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions
Binimetinib, Hydroxychloroquine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 18, 2026, 2:08 AM EDT